Anterogen to sell stem cell treatment

Anterogen, a Korean biotechnology venture, filed an application with the Korea Food and Drug Administration Thursday to market a new drug “Cupistem”, a stem cell treatment for anal fistula in Crohn’s disease.

Crohn’s disease causes chronic inflammation of intestines along with ulcers. Severe ulcers can create a fistula or tiny channel between intestines and adjacent organs, which punctures h...